Indian equity markets closed cautiously on Thursday, October 30, 2025, due to global macroeconomic headwinds from especially the U.S. Federal Reserve’s rate trajectory uncertainty which further spurred the outflows of foreign institutional investors. The Sensex fell 592.67 points to 84,404.46 while the Nifty shed 176.05 points to close at 25,877.85. Barring the broader market pullback, a number of pockets showed strength, particularly in PSU banking stocks, midcap industrials, and healthcare, on the back of strong corporate actions, strategic approvals, and fresh analyst buy calls.
This comprehensive market update dissects the day’s key developments across stock recommendations, banking sector dynamics, mergers & acquisitions (M&A), large-ticket contracts, capacity expansions, and RBI policy insights-all critical for investors navigating India’s evolving equity landscape.
Leading brokerage houses unwrapped a slew of new recommendations for market participants on Thursday, and most seemed to tilt towards undervalued midcaps and PSU heavyweights.
Choice Broking’s Sumeet Bagadia recommended a bullish stance on the following five stocks:
- PDS Ltd: Benefiting from strong order inflows in the oil & gas infrastructure space.
- ABD: Making the right moves to gain traction in the premium spirits segment; eyeing expansion in the rural markets.
- Krishna Institute of Medical Sciences (KIMS): Strong hospital occupancy and diagnostic growth.
- SRM Contractors: Backed by infra pipeline in Tamil Nadu and Andhra Pradesh.
- Vintage Coffee and Beverages: Riding the wave of café culture with aggressive store expansion.
Meanwhile, Aakash K Hindocha of Nuvama Wealth listed ONGC, Graphite India, and SAIL as the best buys. Hindocha said PSU banks are entering into a multi-quarter earnings upcycle on improving asset quality, higher credit growth and government infusion of capital. He expected a strong upside in Bank Nifty, which tested the crucial 58,600 level during Thursday’s session.r adipiscing elit.
“The PSU banking segment is no longer only a value play; it’s a growth story now, supported by systemic reforms and rising credit demand from MSMEs and retail,” Hindocha said.
The October 2025 Bulletin of the Reserve Bank of India carried much-needed reassurance to markets. Key takeaways:
- The headline CPI inflation moderated to 3.3%, well within the RBI's 2-6% target band.
- Domestic consumption remains resilient, with urban demand steady and rural recovery accelerating.
- Above-normal monsoon forecasts for the Rabi season are likely to boost agricultural output and rural incomes.
These macros translated into a strong participation by PSU banks in the Bank Nifty rally. Stocks such as Bank of Baroda, Canara Bank, and Indian Bank outperformed their private peers, reflecting renewed investor confidence in public sector lenders. According to analysts, this may be due to:
- Declining Gross NPA Ratios (now below 4% for most large PSUs)
- Record credit growth in agriculture and priority sectors
- Government's continued capital support under the PSU Bank Recapitalization Plan
The test of 58,600 by the Bank Nifty is considered one important breakout level, which may activate further fresh long positions.
October 30 witnessed significant M&A activity, signaling India Inc.’s strategic consolidation drive:
- Yatra Online Ltd secured NCLT approval for the amalgamation of six subsidiaries—streamlining operations and reducing compliance overhead.
- Asian Energy Services received shareholder and regulatory nod to merge with Oilmax Energy, creating a stronger player in offshore drilling and E&P services.
- Tanla Platforms completed the merger of Gamooga (its CPaaS arm) with Karix Mobile, enhancing its cloud communications stack.
- Rane (Madras) Ltd finalized share allotment post-amalgamation with group entities; Rane Holdings’ stake now stands at 63.80%, ensuring tighter control.
- Piramal Pharma’s subsidiary raised ₹1,600 crore via Optionally Convertible Redeemable Preference Shares (OCRPS), signaling aggressive expansion in global generics and biosimilars.
These moves reflect a broader trend: Indian firms are using M&A to build scale, enter new geographies, and unlock synergies—especially in pharma, IT, and energy.
Government and PSU-led capex continues to drive order inflows for Indian contractors:
- Petronet LNG awarded a ₹360.28 crore civil works contract to Ircon International for the Dahej PDH-PP (Propylene Derivative & Polypropylene) plant—a key step in India’s petrochemical self-reliance.
- RPP Infra Projects secured a ₹125.92 crore contract from DRDO for the National Academy of Defence Financial Management (NADFM) in Pune, underscoring defense infrastructure modernization.
- Ashok Leyland bagged a ₹668.76 crore order from Tamil Nadu State Transport Undertaking (TNSTU) for 3,500 electric and CNG buses—bolstering its clean mobility portfolio.
These contracts not only boost near-term revenues but also validate India’s “Make in India” and green transition commitments.
In a landmark decision, UltraTech Cement’s board approved a ₹10,255 crore capacity expansion plan aimed at reaching 240.8 million tonnes per annum (MTPA) by FY28. The investment will fund:
- New grinding units in Eastern and Central India
- Waste heat recovery systems for ESG compliance
- Logistics optimization via rail and coastal shipping
This move positions UltraTech to capitalize on infrastructure boom (Bharatmala, Sagarmala, PM Awas Yojana) and rising per-capita cement consumption in tier-2/3 cities.
Despite domestic positives, the broader market retreated due to:
- FII selling: Net outflow of ₹2,100 crore in equities over the past three sessions.
- U.S. Fed rate uncertainty: Markets are pricing in a higher-for-longer interest rate regime, strengthening the dollar and pressuring EM assets.
- Profit booking in IT and FMCG after recent rallies.
Top losers included Bharti Airtel (-3.2%), Power Grid (-2.9%), Tech Mahindra (-2.7%), Infosys (-2.5%), and Bajaj Finance (-2.4%)—sectors sensitive to global risk sentiment.
The Indian pharma and healthcare sector emerged as a global M&A hotspot in Q3 2025, with 72 deals worth $3.5 billion—a 40% YoY increase. Key drivers:
- European acquisitions: Indian firms are targeting legacy pharma assets, dermatology portfolios, and biotech platforms in Germany, France, and Italy.
- Generics consolidation: Mid-sized players like Piramal, Granules, and Laurus Labs are acquiring niche EU manufacturers to bypass regulatory hurdles and access established distribution.
This trend aligns with India’s ambition to become a $130 billion pharma exporter by 2030.
While near-term volatility persists due to global cues, domestic fundamentals remain robust. Investors should consider:
- Overweighting PSU banks (SBI, Bank of Baroda, PNB) on valuation and earnings revival.
- Accumulating quality midcaps in infra, healthcare, and specialty chemicals.
- Monitoring FII flows and Fed commentary for entry points in IT and largecaps.
As RBI Governor Shaktikanta Das reiterated in the October bulletin: “India’s growth engine is domestically fueled, resilient, and decoupling from external shocks.”
For long-term investors, Thursday’s dip may offer a strategic entry into fundamentally strong businesses riding India’s capex and consumption wave.
Disclaimer: This article is for informational purposes only and not investment advice. Consult a SEBI-registered advisor before making trading decisions.
Published by Barawakar |Market Wrap– 31 October 2025
Stay informed. Stay ahead.